An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
Transcend Therapeutics
Study ID
NCT07456696
Phase
PHASE3
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TSND-201 — DRUG
    TSND-201 capsules, given orally, once a week for four consecutive weeks
  • Placebo — DRUG
    Placebo capsules, given orally, once a week for four consecutive weeks

Study Details

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Key Dates

Start date
Apr 2, 2026
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TSND-201, Dose Level 1
  • Experimental: TSND-201, Dose Level 2
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score [ Time Frame: Up to 12 weeks ]

Central Contacts

Locations (26)

FacilityCityStateZIPSite coordinators
Preferred Research PartnersLittle RockArkansas72211
Study Coordinator
501-553-9987
Kadima NeuropsychiatryLa JollaCalifornia92037
David Feifel, MD, PhD
858-412-4130
CalNeuro Research GroupLos AngelesCalifornia90025
Michelle Piesman, Study Coordinator
310-208-7144
Catalina Research InstituteMontclairCalifornia91763
Rachelle Phillips, Site Director
Excell ResearchOceansideCalifornia92056
James Lamb
760-758-2222
Inland Psychiatric Medical GroupSan Juan CapistranoCalifornia92675
Vanessa Montanez
909-955-5865
Starlight Clinical ResearchEvergreenColorado80439
David Canter, Co-Founder
970-420-5804
CNS HealthcareJacksonvilleFlorida32256
Study Coordinator
904-281-5757
Segal TrialsLauderhillFlorida33319
Leandro Rueda
Accel Clinical ResearchMaitlandFlorida32751
Ashley Thompson, Clinical Operations Manager
407-644-1165
CNS HealthcareOrlandoFlorida32801
Ashley Westerfeld
Uptown Research InstituteChicagoIllinois60640
Stephen Schneider
Headlands Research - PharmasitePikesvilleMaryland21208
Surya Korn
410-497-8915
Vitalix ClinicalWorcesterMassachusetts01608
Rajvi Patel
508-723-3730
Midwest Research GRoupSaint CharlesMissouri63304
Lindsay Van Winkle
636-496-8032 ext. 5
Center for Emotional Fitness/ Lumina Clinical Research CenterCherry HillNew Jersey08002
Jennifer Mellon
856-857-9500
Global Medical InstitutesPrincetonNew Jersey08540
Thibaud Belleface, Recruitment Specialist
609-921-3555
Bio Behavioral HealthToms RiverNew Jersey08755
Jessica Sutton
732-244-2299
Medical Research NetworkNew YorkNew York10128
Matt Turzilli
212-595-5012
Insight Clinical TrialsIndependenceOhio44131
Elisa Poggi
216-526-1843
Flourish ResearchPlymouth MeetingPennsylvania19462
Landon Este
610-277-8073
Suburban Research AssociatesWest ChesterPennsylvania19380
Head of Site Operations
601-891-9024
Austin Clinical Trial PartnersAustinTexas78737
Kara Chilek
512-521-0595
Haracec Clinical ResearchEl PasoTexas79902
Aghaegbulam Uga, MD
915-200-1144
Inner Space ResearchOremUtah84058
Inner Space Research
801-871-5516
Seattle Neuropsychiatric Treatment Center (NTC)SeattleWashington98104
Seattle NTC Research Team
206-467-6300

Find similar trials in Little Rock, AR

Related Studies